Literature DB >> 21087444

Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition.

M Kverka1, Z Zakostelska, K Klimesova, D Sokol, T Hudcovic, T Hrncir, P Rossmann, J Mrazek, J Kopecny, E F Verdu, H Tlaskalova-Hogenova.   

Abstract

Commensal bacteria have been shown to modulate the host mucosal immune system. Here, we report that oral treatment of BALB/c mice with components from the commensal, Parabacteroides distasonis, significantly reduces the severity of intestinal inflammation in murine models of acute and chronic colitis induced by dextran sulphate sodium (DSS). The membranous fraction of P. distasonis (mPd) prevented DSS-induced increases in several proinflammatory cytokines, increased mPd-specific serum antibodies and stabilized the intestinal microbial ecology. The anti-colitic effect of oral mPd was not observed in severe combined immunodeficient mice and probably involved induction of specific antibody responses and stabilization of the intestinal microbiota. Our results suggest that specific bacterial components derived from the commensal bacterium, P. distasonis, may be useful in the development of new therapeutic strategies for chronic inflammatory disorders such as inflammatory bowel disease.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21087444      PMCID: PMC3043316          DOI: 10.1111/j.1365-2249.2010.04286.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

Review 1.  Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases.

Authors:  Helena Tlaskalová-Hogenová; Renata Stepánková; Tomás Hudcovic; Ludmila Tucková; Bozena Cukrowska; Rája Lodinová-Zádníková; Hana Kozáková; Pavel Rossmann; Jirina Bártová; Dan Sokol; David P Funda; Dana Borovská; Zuzana Reháková; Jirí Sinkora; Jaroslav Hofman; Pavel Drastich; Alena Kokesová
Journal:  Immunol Lett       Date:  2004-05-15       Impact factor: 3.685

Review 2.  Host-bacterial interactions in inflammatory bowel disease.

Authors:  Yashwant R Mahida; Vivien E Rolfe
Journal:  Clin Sci (Lond)       Date:  2004-10       Impact factor: 6.124

3.  Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum.

Authors:  P Rutgeerts; K Goboes; M Peeters; M Hiele; F Penninckx; R Aerts; R Kerremans; G Vantrappen
Journal:  Lancet       Date:  1991-09-28       Impact factor: 79.321

4.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.

Authors:  I Okayasu; S Hatakeyama; M Yamada; T Ohkusa; Y Inagaki; R Nakaya
Journal:  Gastroenterology       Date:  1990-03       Impact factor: 22.682

5.  The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice.

Authors:  T Hudcovic; R Stĕpánková; J Cebra; H Tlaskalová-Hogenová
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

6.  Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.

Authors:  T Mimura; F Rizzello; U Helwig; G Poggioli; S Schreiber; I C Talbot; R J Nicholls; P Gionchetti; M Campieri; M A Kamm
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

7.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

Authors:  W Kruis; P Fric; J Pokrotnieks; M Lukás; B Fixa; M Kascák; M A Kamm; J Weismueller; C Beglinger; M Stolte; C Wolff; J Schulze
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

8.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis.

Authors:  H S Cooper; S N Murthy; R S Shah; D J Sedergran
Journal:  Lab Invest       Date:  1993-08       Impact factor: 5.662

9.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

Authors:  Daniel Rachmilewitz; Kyoko Katakura; Fanny Karmeli; Tomoko Hayashi; Constantin Reinus; Bernard Rudensky; Shizuo Akira; Kiyoshi Takeda; Jongdae Lee; Kenji Takabayashi; Eyal Raz
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

10.  Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon.

Authors:  P Seksik; L Rigottier-Gois; G Gramet; M Sutren; P Pochart; P Marteau; R Jian; J Doré
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

View more
  113 in total

Review 1.  The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases.

Authors:  Helena Tlaskalová-Hogenová; Renata Stěpánková; Hana Kozáková; Tomáš Hudcovic; Luca Vannucci; Ludmila Tučková; Pavel Rossmann; Tomáš Hrnčíř; Miloslav Kverka; Zuzana Zákostelská; Klára Klimešová; Jaroslava Přibylová; Jiřina Bártová; Daniel Sanchez; Petra Fundová; Dana Borovská; Dagmar Srůtková; Zdeněk Zídek; Martin Schwarzer; Pavel Drastich; David P Funda
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

2.  Targeting gut microbiota and barrier function with prebiotics to alleviate autoimmune manifestations in NOD mice.

Authors:  Camilla H F Hansen; Christian S Larsen; Henriette O Petersson; Line F Zachariassen; Andreas Vegge; Charlotte Lauridsen; Witold Kot; Łukasz Krych; Dennis S Nielsen; Axel K Hansen
Journal:  Diabetologia       Date:  2019-05-28       Impact factor: 10.122

3.  Low dietary iron intake restrains the intestinal inflammatory response and pathology of enteric infection by food-borne bacterial pathogens.

Authors:  Guus A M Kortman; Michelle L M Mulder; Thijs J W Richters; Nanda K N Shanmugam; Estela Trebicka; Jos Boekhorst; Harro M Timmerman; Rian Roelofs; Erwin T Wiegerinck; Coby M Laarakkers; Dorine W Swinkels; Albert Bolhuis; Bobby J Cherayil; Harold Tjalsma
Journal:  Eur J Immunol       Date:  2015-06-23       Impact factor: 5.532

4.  Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.

Authors:  Vinita Jacob; Carl Crawford; Shirley Cohen-Mekelburg; Monica Viladomiu; Gregory G Putzel; Yecheskel Schneider; Fatiha Chabouni; Sarah OʼNeil; Brian Bosworth; Viola Woo; Nadim J Ajami; Joseph F Petrosino; Ylaine Gerardin; Zain Kassam; Mark Smith; Iliyan D Iliev; Gregory F Sonnenberg; David Artis; Ellen Scherl; Randy S Longman
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

Review 5.  Inflammation and colorectal cancer: colitis-associated neoplasia.

Authors:  Sergei I Grivennikov
Journal:  Semin Immunopathol       Date:  2012-11-16       Impact factor: 9.623

Review 6.  Are vaccination models suitable to determine whether probiotics have beneficial health effects in the general population?

Authors:  Nicholas P West; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

Review 7.  Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Authors:  Christopher G Mayne; Calvin B Williams
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

Review 8.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

9.  Diverse Intestinal Bacteria Contain Putative Zwitterionic Capsular Polysaccharides with Anti-inflammatory Properties.

Authors:  C Preston Neff; Matthew E Rhodes; Kathleen L Arnolds; Colm B Collins; Jody Donnelly; Nichole Nusbacher; Paul Jedlicka; Jennifer M Schneider; Martin D McCarter; Michael Shaffer; Sarkis K Mazmanian; Brent E Palmer; Catherine A Lozupone
Journal:  Cell Host Microbe       Date:  2016-09-29       Impact factor: 21.023

10.  Differential induction of antimicrobial REGIII by the intestinal microbiota and Bifidobacterium breve NCC2950.

Authors:  Jane M M Natividad; Christina L Hayes; Jean-Paul Motta; Jennifer Jury; Heather J Galipeau; Vivek Philip; Clara L Garcia-Rodenas; Hiroshi Kiyama; Premysl Bercik; Elena F Verdu
Journal:  Appl Environ Microbiol       Date:  2013-10-04       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.